Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
raised lesions; Pain eye; Itching; postherpetic neuralgia; This non-serious case was reported by a consumer via call center representative and described the occurrence of post herpetic neuralgia in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included ophthalmic herpes zoster (Herpes zoster ophthalmicus). On 22-AUG-2025, the patient received the 1st dose of Shingrix. In AUG-2025, an unknown time after receiving Shingrix, the patient experienced post herpetic neuralgia (Verbatim: postherpetic neuralgia) and pruritus (Verbatim: Itching). In SEP-2025, the patient experienced skin lesion (Verbatim: raised lesions) and eye pain (Verbatim: Pain eye). The patient was treated with valaciclovir hydrochloride (Valtrex). The outcome of the post herpetic neuralgia, skin lesion, eye pain and pruritus were resolving. It was unknown if the reporter considered the post herpetic neuralgia, skin lesion, eye pain and pruritus to be related to Shingrix. It was unknown if the company considered the post herpetic neuralgia, skin lesion, eye pain and pruritus to be related to Shingrix. Additional Information: GSK Receipt Date: 01-OCT-2025 The patient reported that she was expecting to have a reaction to the Shingrix dose due to her history of Herpes Zoster Ophthalmicas, first diagnosed in August of 2022. The patient received her Shingrix dose 1 on 22nd August 2025. The patient experienced postherpetic neuralgia and itching shortly after the vaccination was received, and two weeks later noticed raised lesions. The patient had medicated the outbreak with Valtrex and she stated that it had not exacerbated and was slowly resolving.
Ophthalmic herpes zoster (Herpes zoster ophthalmicus)